Yang Manli, You Jinhui
Department of Nuclear Medicine, the Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R.China.
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2021 Apr 25;38(2):399-404. doi: 10.7507/1001-5515.202010004.
Because of the unobvious early symptoms and low 5-year survival rate, the early diagnosis and treatment is of great significance for patients with non-small cell lung cancer. Glucose transporter-1 is the most widely distributed glucose transporters in various tissue cells in the human body, whose expression in non-small cell lung cancer is closely related to the histological types, lymph node metastasis, degree of differentiation, progression and prognosis. F-FDG PET/CT imaging, a molecular imaging diagnostic method, is based on the characteristics of glucose metabolism in malignant tumors, which has been widely applied in the cancer diagnosis, stage division, evaluation of therapeutic effects and prognosis evaluation. Glucose transporter-1 is regulated and influenced by many factors, and it is closely related to F-FDG PET/CT imaging. This article briefly reviews the progress in the clinical application and correlation between glucose transporter-1 and F-FDG PET/CT imaging for non-small cell lung cancer, in order to improve the diagnosis and treatment of lung cancer.
由于早期症状不明显且5年生存率低，早期诊断和治疗对非小细胞肺癌患者具有重要意义。葡萄糖转运蛋白1是人体各种组织细胞中分布最广泛的葡萄糖转运蛋白，其在非小细胞肺癌中的表达与组织学类型、淋巴结转移、分化程度、进展及预后密切相关。F-FDG PET/CT成像作为一种分子影像诊断方法，基于恶性肿瘤的葡萄糖代谢特征，已广泛应用于癌症诊断、分期、疗效评估及预后评价。葡萄糖转运蛋白1受多种因素调控和影响，且与F-FDG PET/CT成像密切相关。本文简要综述葡萄糖转运蛋白1与F-FDG PET/CT成像在非小细胞肺癌临床应用及相关性方面的研究进展，以期提高肺癌的诊断与治疗水平。
